Christopher Leamon

Company: Fusion Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

Clinical Advances of 225Ac-targeted Antibody & Small Molecule-based Agents & Revealing Preclinical Insights from Immune Checkpoint Combination Approaches 11:45 am

Outlining why 225Ac is an attractive radioisotope for targeted therapy Exploring clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (a phase 2/3 study) Revealing rational drug combinations for targeted alpha therapeuticsRead more

day: Day One LSC AM